Navigation Links
Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies
Date:6/19/2013

PRINCETON, N.J., June 19, 2013 /PRNewswire-iReach/ -- In its first major deal, Belrose Pharma, a new specialty pharmaceutical company dedicated to advancing development of the next generation of innovative injectable and sustained release drug therapies in patient disease populations with high unmet medical needs, today announced the acquisition of Enzon Pharmaceutical's PEGylation Linker Technology (Customized Linker Technology®) platform and associated product pipeline. Acquisition of this technology will enable Belrose Pharma to accelerate creation of improved biologic and small molecule therapies with better treatment outcomes for patients with life-threatening diseases such as breast cancer and pediatric neuroblastoma, and orphan drug diseases such as hereditary angioedema (HAE).    

Through this transaction, Belrose Pharma has added to its portfolio both "traditional" permanent PEGylation and the lesser-known releasable PEGylation technologies, as well as compounds based on both technologies. Polyethylene glycol (PEG), when permanently linked to certain compounds, has a long track record of enabling high-value commercial products through sometimes dramatic improvements in in vivo circulation, toxicity, and efficacy.  The lesser-known releasable PEGylation technique provides a different set of clinical benefits – including several targeted release options without a corresponding reduction in potency, improved drug loading, pharmacokinetics, and efficacy, and a simplified and potentially shorter clinical path to market.

"This acquisition of Enzon's permanent and releasable Customized Linker Technology® significantly strengthens our platform for accelerating the development of more patient-friendly and effective therapies in a range of specialty disease categories," said Belrose Pharma founder and CEO, Eric Gilbert. "We look forward to being a positive force for bringing new therapies and improved formulations of existing therapies to the global healthcare marketplace and to critically ill patient populations."

Belrose will leverage the value of the assets purchased from Enzon within Belrose's two key business areas: (a) advancing development of internal clinical and pre-clinical compounds, and (b) product development for third party customers seeking to improve both early clinical and mid-lifecycle products using Customized Linker Technology®, where alternative technologies such as nanoparticles and lipid formulations are less suitable. 

Belrose will continue development of two programs acquired from Enzon.  The first program is PEG-SN38 (formerly EZN-2208), a Phase III-ready PEGylated conjugate of SN38 with improved properties including parenteral delivery, increased solubility, higher exposure, more profound deoxyribonucleic acid (DNA) damage, inhibition of angiogenesis, and longer half-life compared with native SN38. PEG-SN38 produced positive responses in clinical trials for metastatic breast cancer and pediatric neuroblastoma.  The second program is PEG-C1 Esterase Inhibitor (formerly EZN-3008), a preclinical PEGylated form of plasma-derived C1-Esterase Inhibitor (C1-INH) offering the significant improvement of weekly or bi-weekly subcutaneous or intravenous injections to HAE patients currently limited to twice-weekly infusions for prophylactic use.

Subsequent to the completion of this acquisition, several members of the core technical team that was formerly involved in Enzon's extensive research, development, and commercialization of the permanent and releasable Customized Linker Technology® have joined Belrose Pharma.

About PEGylation Technology

PEGylation technology has successfully enabled regulatory approval and launch of a series of breakthrough pharmaceutical products since Enzon first pioneered the technique in the 1980s.  Since FDA approval of the first PEGylated product, Adagen® (PEG-bovine adenosine deaminase) in 1990, cumulative worldwide revenue of all PEGylated pharmaceutical products  has exceeded $20 billion.  PEGylation has been validated for compounds including enzymes, peptides, small molecules and antibody fragments, with the chemical attachment of polyethylene glycol (PEG) used to improve those compounds' half lives and toxicity profiles, among other patient benefits achieved by maximizing the inherent biological activity of the native molecules.

About Belrose Pharma Inc.

Belrose Pharma Inc. (Princeton, NJ) is a specialty pharmaceutical company that operates two related businesses: (a) advancing development of internal clinical and pre-clinical compounds, and (b) product development for third party customers seeking to improve both early clinical and mid-lifecycle products using a range of  technologies including Customized Linker Technology®. Belrose combines a new senior commercial management team with a core technical team previously involved in development and commercialization efforts using customized PEGylation linker technologies.  Further information about Belrose can be found on the Company's website at www.belrosepharma.com.

Note to Media and Investors

Belrose Pharma has been formed by new investors to develop pharmaceutical products with technologies and clinical programs acquired from Enzon Pharmaceuticals and others.  The Belrose Pharma investors have no substantive relationship to any major equity or debt holder in Enzon Pharmaceuticals. Enzon Pharmaceuticals also does not have any equity ownership in Belrose Pharma.

Partnering Contact:

Michael King

Chief Commercial Officer

(609) 454-2989

michael.king@belrosepharma.com

Media Contact:

Tony Riggio Belrose Pharma Inc., (609) 454-2995, tonyr@belrosepharma.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Belrose Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings
2. Pharma IQ Presents the Latest Trends in Clinical Trial Supply
3. Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes
4. Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Valeant Pharmaceuticals Prices Public Offering Of Common Shares
6. Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints
7. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
8. Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House
9. Valeant Pharmaceuticals Announces Public Offering Of Common Shares
10. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
11. Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  SI-BONE, Inc., a medical device company ... ("iFuse"), a minimally invasive surgical (MIS) device indicated for fusion for ... Services, Inc. (NGS), the Medicare Administrative Contractor (MAC) covering the states ... Maine , Massachusetts , ... New York , Rhode Island , ...
(Date:2/12/2016)... and SEOUL, South Korea ... Menarini and Macrogen, Inc. today announced they will ... innovative procedures for precision medicine in cancer. The ... Biosystems, DEPArray™ digital-sorting technology with Macrogen,s high-throughput Next ... certified under the Clinical Laboratory Improvement Amendments (CLIA) ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis ... completed a $47.1 million Series D preferred ... Asset Management, Hillhouse Capital Group and venBio ... Venture Investments, AJU IB Investment, and Epidarex ... used to further advance clinical trials in ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The ... uncovers what he says are the real facts surrounding all those Bible stories. For ... and Sunday school teachers, and Yisrayl says there is more to these than just ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Dignity Health ... General Hospital Emergency Room –Mesa. The new facility is licensed under Dignity ... , “Dr. Bingham is an excellent leader and will ensure our new freestanding emergency ...
(Date:2/11/2016)... ... 11, 2016 , ... SPH Analytics announced today that ... health solutions, MDinsight® and IndiGO®, for its primary care clinicians. The 3-year partnership ... the contract were not disclosed. , As the healthcare market moves towards quality-based ...
(Date:2/11/2016)... ... , ... Florida Hospital presents Heart Health Awareness night on Sunday February 14th, ... Amalie Arena. The puck drops at 6:00pm, but fans will have the opportunity to ... the game. The MEGA Heart will be located on Ford Thunder Alley and provide ...
(Date:2/11/2016)... Chicago, IL (PRWEB) , ... February 11, 2016 ... ... dedicated to the healthcare industry, ranked among the top five firms in the ... Services and HIT Implementation Support and Staffing. KLAS is a research and insights ...
Breaking Medicine News(10 mins):